|
|
Volumn 46, Issue 5, 2017, Pages 364-370
|
|
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
RECOMBINANT ERYTHROPOIETIN;
BIOSIMILAR AGENT;
HEMOGLOBIN;
ACUTE RESPIRATORY FAILURE;
ADULT;
ARTICLE;
BLADDER CANCER;
BODY MASS;
BRAIN ISCHEMIA;
CEREBROVASCULAR ACCIDENT;
CHRONIC KIDNEY FAILURE;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONGESTIVE HEART FAILURE;
CONTROLLED STUDY;
DIARRHEA;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG SAFETY;
END STAGE RENAL DISEASE;
ENDOCARDITIS;
FEMALE;
FOLLOW UP;
HEART INFARCTION;
HEMODIALYSIS;
HEMOGLOBIN DETERMINATION;
HUMAN;
HYPERKALEMIA;
HYPERTENSION;
IMMUNE RESPONSE;
IMMUNOGENICITY;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
NAUSEA;
PERITONEAL DIALYSIS;
PRIORITY JOURNAL;
RADIOIMMUNOPRECIPITATION;
RANDOMIZED CONTROLLED TRIAL;
STUDY DESIGN;
THROMBOEMBOLISM;
UREMIA;
AGED;
ANEMIA;
BLOOD;
MIDDLE AGED;
THERAPEUTIC EQUIVALENCE;
TREATMENT OUTCOME;
UNITED STATES;
VERY ELDERLY;
YOUNG ADULT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANEMIA;
BIOSIMILAR PHARMACEUTICALS;
DOUBLE-BLIND METHOD;
EPOETIN ALFA;
FEMALE;
HEMATINICS;
HEMOGLOBINS;
HUMANS;
KIDNEY FAILURE, CHRONIC;
MALE;
MIDDLE AGED;
RENAL DIALYSIS;
THERAPEUTIC EQUIVALENCY;
TREATMENT OUTCOME;
UNITED STATES;
YOUNG ADULT;
|
|
EID: 85033367205
PISSN: 02508095
EISSN: 14219670
Source Type: Journal
DOI: 10.1159/000481736 Document Type: Article |
|
Times cited : (9)
|
|
References (5)
|
